Related references
Note: Only part of the references are listed.Eosinophil-rich linear IgA bullous dermatosis induced by mRNA COVID-19 booster vaccine
William J. Nahm et al.
JOURNAL OF CUTANEOUS PATHOLOGY (2023)
Severe bullous pemphigoid following Covid-19 vaccination resistant to rituximab and successfully treated with dupilumab
Maria E. Baffa et al.
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY (2023)
COVID-19 in pemphigus vulgaris patients with previous rituximab therapy: a tele-medicine experience
Mohammad Shahidi-Dadras et al.
JOURNAL OF DERMATOLOGICAL TREATMENT (2022)
An unusual presentation of pemphigus foliaceus following COVID-19 vaccination
Angelyn Chen Yin Lua et al.
AUSTRALASIAN JOURNAL OF DERMATOLOGY (2022)
Bullous pemphigoid after SARS-CoV-2 vaccination: spike-protein-directed immunofluorescence confocal microscopy and T-cell-receptor studies
T. Gambichler et al.
BRITISH JOURNAL OF DERMATOLOGY (2022)
COVID-19 vaccine acceptance and hesitancy in patients with immunobullous diseases: a cross-sectional study of the International Pemphigus and Pemphigoid Foundation
M. Kasperkiewicz et al.
BRITISH JOURNAL OF DERMATOLOGY (2022)
Linear IgA bullous dermatosis following Oxford AstraZeneca COVID-19 vaccine
F. Hali et al.
CLINICAL AND EXPERIMENTAL DERMATOLOGY (2022)
COVID vaccination in patients under treatment with rituximab: A presentation of two cases from Iran and a review of the current knowledge with a specific focus on pemphigus
Parvaneh Hatami et al.
DERMATOLOGIC THERAPY (2022)
Bullous pemphigoid triggered by COVID-19 vaccine: Rapid resolution with corticosteroid therapy
Massimo Dell'Antonia et al.
DERMATOLOGIC THERAPY (2022)
Pemphigus vulgaris relapse during the coronavirus disease pandemic
Marwah Adly Saleh et al.
DERMATOLOGIC THERAPY (2022)
New-onset bullous pemphigoid after inactivated Covid-19 vaccine: Synergistic effect of the Covid-19 vaccine and vildagliptin
Ecem Bostan et al.
DERMATOLOGIC THERAPY (2022)
New onset of pemphigus foliaceus following BNT162b2 vaccine
Sebnem Yildirici et al.
DERMATOLOGIC THERAPY (2022)
Pemphigus vulgaris after SARS-CoV-2 vaccination: A case with new-onset and two cases with severe aggravation
Gulsen Akoglu
DERMATOLOGIC THERAPY (2022)
Can Covid-19 vaccines cause or exacerbate bullous pemphigoid? A report of seven cases from one center
Elif Afacan et al.
INTERNATIONAL JOURNAL OF DERMATOLOGY (2022)
Incidence and severity of COVID-19 in patients with autoimmune blistering skin diseases: A nationwide study
Pascal Joly et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2022)
Bullous pemphigoid in a young male after COVID-19 mRNA vaccine: a report and brief literature review
M. Pauluzzi et al.
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY (2022)
Biphasic bullous pemphigoid starting after first dose and boosted by second dose of mRNA-1273 vaccine in an 84-year-old female with polymorbidity and polypharmacy
V. Schmidt et al.
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY (2022)
Development of pemphigus vulgaris following mRNA SARS-CoV-19 BNT162b2 vaccination in an 89-year-old patient
G. V. Knechtl et al.
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY (2022)
Psoriasis flare-up after AZD1222 and BNT162b2 COVID-19 mRNA vaccines: report of twelve cases from a single centre
D. Koumaki et al.
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY (2022)
Incident bullous pemphigoid in a psoriatic patient following mRNA-1273 SARS-CoV-2 vaccination
W. -K. Hung et al.
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY (2022)
Oral pemphigus after COVID-19 vaccination
Kobkan Thongprasom et al.
ORAL DISEASES (2022)
Development of pemphigus vulgaris after the second dose of the mRNA-1273 SARS-Cov-2 vaccine
Ioannis G. Koutlas et al.
ORAL DISEASES (2022)
Vesiculobullous skin reactions induced by COVID-19 mRNA vaccine: report of four cases and review of the literature
P. Coto-Segura et al.
CLINICAL AND EXPERIMENTAL DERMATOLOGY (2022)
Bullous pemphigoid induced by the AstraZeneca COVID-19 vaccine
F. -Z Agharbi et al.
ANNALES DE DERMATOLOGIE ET DE VENEREOLOGIE (2022)
Evaluating risk of bullous pemphigoid after mRNA COVID-19 vaccination
Morgan Birabaharan et al.
BRITISH JOURNAL OF DERMATOLOGY (2022)
COVID-19 severity and SARS-Cov-2 vaccine safety in pemphigus patients
Zuleyha Ozgen et al.
DERMATOLOGIC THERAPY (2022)
Bullous pemphigoid after inactivated COVID-19 vaccination: Case report
Yingjie Zhang et al.
DERMATOLOGIC THERAPY (2022)
Reply to New-onset bullous pemphigoid after inactivated Covid-19 vaccine: Synergistic effect of the Covid-19 vaccine and vildagliptin
Carlo Alberto Maronese et al.
DERMATOLOGIC THERAPY (2022)
De novo severe pemphigus vulgaris following SARS-CoV-2 vaccination with BBIBP-CorV
Zahra Saffarian et al.
DERMATOLOGIC THERAPY (2022)
New-onset bullous pemphigoid and flare of pre-existing bullous pemphigoid after the third dose of the COVID-19 vaccine
Federico Bardazzi et al.
DERMATOLOGIC THERAPY (2022)
Clinical and histopathological spectrum of delayed adverse cutaneous reactions following COVID-19 vaccination
Valerie Larson et al.
JOURNAL OF CUTANEOUS PATHOLOGY (2022)
Clinical and pathologic correlation of cutaneous COVID-19 vaccine reactions including V-REPP: A registry-based study
Devon E. McMahon et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2022)
A case of bullous pemphigoid after the SARS-CoV-2 mRNA vaccine
J. Young et al.
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY (2022)
Association between vaccination and immunobullous disorders: a brief, updated systematic review with focus on COVID-19
M. Kasperkiewicz et al.
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY (2022)
Autoimmune mucocutaneous blistering diseases after SARS-Cov-2 vaccination: A Case report of Pemphigus Vulgaris and a literature review
Elena Calabria et al.
PATHOLOGY RESEARCH AND PRACTICE (2022)
Development of severe pemphigus vulgaris following ChAdOx1 nCoV-19 vaccination and review of literature
Ajeet Singh et al.
JOURNAL OF COSMETIC DERMATOLOGY (2022)
Autoimmune Skin Disease Exacerbations Following COVID-19 Vaccination
Grant Sprow et al.
FRONTIERS IN IMMUNOLOGY (2022)
Bullous Pemphigoid Associated With COVID-19 Vaccines: An Italian Multicentre Study
Carlo Alberto Maronese et al.
FRONTIERS IN MEDICINE (2022)
Breakthrough SARS-CoV-2 infections with the delta (B.1.617.2) variant in vaccinated patients with immune-mediated inflammatory diseases using immunosuppressants: a substudy of two prospective cohort studies
Laura Boekel et al.
LANCET RHEUMATOLOGY (2022)
Bullous pemphigoid after second dose of mRNA- (Pfizer-BioNTech) Covid-19 vaccine: A case report
Fouad Alshammari et al.
ANNALS OF MEDICINE AND SURGERY (2022)
Adverse outcome and severity of COVID-19 in patients with autoimmune bullous diseases: A historical cohort study
Fateme Shirzad Moghadam et al.
DERMATOLOGIC THERAPY (2022)
Cutaneous manifestations following COVID-19 vaccination: A report of 25 cases
Safoura Shakoei et al.
DERMATOLOGIC THERAPY (2022)
Influence of Covid-19 vaccination on immune-mediated skin diseases
N. A. Alelq et al.
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY (2022)
Cutaneous adverse reactions following SARS-CoV-2 vaccine booster dose: a real-life multicentre experience
G. Avallone et al.
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY (2022)
Exacerbation of Autoimmune Bullous Diseases After Severe Acute Respiratory Syndrome Coronavirus 2 Vaccination: Is There Any Association?
Nika Kianfar et al.
FRONTIERS IN MEDICINE (2022)
Risk of severe COVID-19 outcomes associated with immune-mediated inflammatory diseases and immune-modifying therapies: a nationwide cohort study in the OpenSAFELY platform
Brian MacKenna et al.
LANCET RHEUMATOLOGY (2022)
New onset of pemphigus foliaceus following BBIBP COVID-19 vaccine
Mohammadreza Pourani et al.
DERMATOLOGIC THERAPY (2022)
Five cases of new-onset pemphigus following vaccinations against coronavirus disease 2019
Alberto Corra et al.
JOURNAL OF DERMATOLOGY (2022)
A new eruption of bullous pemphigoid following mRNA COVID-19 vaccination
Bryan Daines et al.
Dermatology Online Journal (2022)
New-onset bullous pemphigoid triggered by AstraZeneca COVID-19 vaccine
Yin-Cheng Chao et al.
DERMATOLOGICA SINICA (2022)
Association between COVID-19 vaccination and bullous pemphigoid a case series and literature review
Vincent Wan et al.
SAGE OPEN MEDICAL CASE REPORTS (2022)
Dyshidrosiform Bullous Pemphigoid Triggered by COVID-19 Vaccination
Mohammed Shanshal
CUREUS JOURNAL OF MEDICAL SCIENCE (2022)
Bullous Pemphigoid Following the Moderna mRNA-1273 Vaccine
Amar D. Desai et al.
CUREUS JOURNAL OF MEDICAL SCIENCE (2022)
Autoimmune Bullous Dermatosis Following COVID-19 Vaccination: A Series of Five Cases
Fouzia Sr Hali et al.
CUREUS JOURNAL OF MEDICAL SCIENCE (2022)
An unusual presentation of pemphigus foliaceus following COVID-19 vaccination
Angelyn Chen Yin Lua et al.
AUSTRALASIAN JOURNAL OF DERMATOLOGY (2022)
Rituximab for granulomatosis with polyangiitis in the pandemic of covid-19: lessons from a case with severe pneumonia
Philippe Guilpain et al.
ANNALS OF THE RHEUMATIC DISEASES (2021)
Response to: 'Severe COVID-19 associated pneumonia in 3 patients with systemic sclerosis treated with rituximab' by Avouac et al
Philippe Guilpain et al.
ANNALS OF THE RHEUMATIC DISEASES (2021)
COVID-19 outbreak and autoimmune bullous diseases: A systematic review of published cases
Michael Kasperkiewicz
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2021)
Predictors ofCOVID-19 severity: A literature review
Benjamin Gallo Marin et al.
REVIEWS IN MEDICAL VIROLOGY (2021)
Can rituximab be used in the treatment of pemphigus vulgaris during the COVID-19 pandemic?
Tugba Kevser Uzuncakmak et al.
DERMATOLOGIC THERAPY (2021)
Characteristics and outcomes of COVID-19 in patients with autoimmune bullous diseases: A retrospective cohort study
Hamidreza Mahmoudi et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2021)
SARS-CoV-2 Infection Hospitalization Rate and Infection Fatality Rate Among the Non-Congregate Population in Connecticut
Shiwani Mahajan et al.
AMERICAN JOURNAL OF MEDICINE (2021)
Factors associated with COVID-19-related death in people with rheumatic diseases: results from the COVID-19 Global Rheumatology Alliance physician-reported registry
Anja Strangfeld et al.
ANNALS OF THE RHEUMATIC DISEASES (2021)
The SARS-CoV-2 as an instrumental trigger of autoimmunity
Arad Dotan et al.
AUTOIMMUNITY REVIEWS (2021)
SARS-CoV-2 vaccination in rituximab-treated patients: evidence for impaired humoral but inducible cellular immune response
Michael Markus Bonelli et al.
ANNALS OF THE RHEUMATIC DISEASES (2021)
Inactivated COVID-19 Vaccine Induces a Low Humoral Immune Response in a Subset of Dermatological Patients Receiving Immunosuppressants
Chutima Seree-aphinan et al.
FRONTIERS IN MEDICINE (2021)
The risk of COVID-19 in patients with bullous pemphigoid and pemphigus: A population-based cohort study
Khalaf Kridin et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2021)
COVID-19 pandemic and autoimmune bullous diseases: a cross-sectional study of the International Pemphigus and Pemphigoid Foundation
M. Kasperkiewicz et al.
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY (2021)
Case Report: Complete and Fast Recovery From Severe COVID-19 in a Pemphigus Patient Treated With Rituximab
Jo Linda Sinagra et al.
FRONTIERS IN IMMUNOLOGY (2021)
COVID-19 outcomes in patients with autoimmune blistering disease
E. Hwang et al.
BRITISH JOURNAL OF DERMATOLOGY (2021)
Subepidermal blistering eruptions, including bullous pemphigoid, following COVID-19 vaccination
Mary M. Tomayko et al.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2021)
Case of bullous pemphigoid following coronavirus disease 2019 vaccination
Kenta Nakamura et al.
JOURNAL OF DERMATOLOGY (2021)
Development of severe pemphigus vulgaris following SARS-CoV-2 vaccination with BNT162b2
F. Solimani et al.
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY (2021)
The first dose of COVID-19 vaccine may trigger pemphigus and bullous pemphigoid flares: is the second dose therefore contraindicated?
G. Damiani et al.
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY (2021)
Baseline Characteristics and Outcomes of 1591 Patients Infected With SARS-CoV-2 Admitted to ICUs of the Lombardy Region, Italy
Giacomo Grasselli et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2020)
The value of clinical parameters in predicting the severity of COVID-19
Weifeng Shang et al.
JOURNAL OF MEDICAL VIROLOGY (2020)
Should SARS-CoV-2 influence immunosuppressive therapy for autoimmune blistering diseases?
A. Di Altobrando et al.
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY (2020)
Expert recommendations for the management of autoimmune bullous diseases during the COVID-19 pandemic
M. Kasperkiewicz et al.
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY (2020)
Occurrence of SARS-CoV-2 during mycophenolate mofetil treatment for pemphigus
R. Balestri et al.
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY (2020)
Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study
Fei Zhou et al.
LANCET (2020)
Patients with bullous skin disease in a high-epidemic COVID-19 area, Bergamo, Italy
A. Carugno et al.
BRITISH JOURNAL OF DERMATOLOGY (2020)
Incidence of COVID-19 in Patients With Rheumatic Diseases Treated With Targeted Immunosuppressive Drugs: What Can We Learn From Observational Data?
Ennio Giulio Favalli et al.
ARTHRITIS & RHEUMATOLOGY (2020)
Case characteristics, resource use, and outcomes of 10 021 patients with COVID-19 admitted to 920 German hospitals: an observational study
Christian Karagiannidis et al.
LANCET RESPIRATORY MEDICINE (2020)
Comparing SARS-CoV-2 with SARS-CoV and influenza pandemics
Eskild Petersen et al.
LANCET INFECTIOUS DISEASES (2020)
Factors associated with COVID-19-related death using OpenSAFELY
Elizabeth J. Williamson et al.
NATURE (2020)
Aggressive course of pemphigus vulgaris following COVID-19 infection
Fariba Ghalamkarpour et al.
DERMATOLOGIC THERAPY (2020)
Incidence of COVID-19 in a cohort of adult and paediatric patients with rheumatic diseases treated with targeted biologic and synthetic disease-modifying anti-rheumatic drugs
Xabier Michelena et al.
SEMINARS IN ARTHRITIS AND RHEUMATISM (2020)
High rates of severe disease and death due to SARS-CoV-2 infection in rheumatic disease patients treated with rituximab: a descriptive study
Jesus Loarce-Martos et al.
RHEUMATOLOGY INTERNATIONAL (2020)
Use of rituximab and the risk of adverse clinical outcomes in COVID-19 patients with systemic rheumatic disease
Chia Siang Kow et al.
RHEUMATOLOGY INTERNATIONAL (2020)
Efficacy of Repeated Courses of Rituximab as Treatment for Pemphigus Vulgaris
Sharon Baum et al.
ACTA DERMATO-VENEREOLOGICA (2020)
Age-specific mortality and immunity patterns of SARS-CoV-2
Megan O'Driscoll et al.
NATURE (2020)
Efficacy, immunogenicity and safety of vaccination in adult patients with autoimmune inflammatory rheumatic diseases: a systematic literature review for the 2019 update of EULAR recommendations
Christien Rondaan et al.
RMD OPEN (2019)
Exacerbation of pemphigus after influenza vaccination
C. De Simone et al.
CLINICAL AND EXPERIMENTAL DERMATOLOGY (2008)
Maintenance of long-lived plasma cells and serological memory despite mature and memory B cell depletion during CD20 immunotherapy in mice
David J. DiLillo et al.
JOURNAL OF IMMUNOLOGY (2008)
Exacerbation of pemphigus foliaceus after tetanus vaccination accompanied by synthesis of auto-antibodies against paraneoplastic pemphigus antigens
K Korang et al.
ACTA DERMATO-VENEREOLOGICA (2002)